TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06706115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intranasal human breast milk
Description: The information in the Physiologic Parameter Follow-up Form will be recorded by the investigator just 5 minutes before the intervention. The researcher will drip 0.2 ml of breast milk at room temperature (approximately 22 °C) into the nose of the infant lying in the supine position, 0.1 ml in the right nose-0.1 ml in the left nose. 5 minutes after the intervention (T1), 15 minutes after the intervention (T2) and 30 minutes after the intervention (T3), the data in the Physiologic Parameter Follow-up Form will be recorded by the researcher. After intranasal breast milk administration, the baby will be fed by the neonatal nurse as in routine practice. The implementation of the intervention in the study will last for three days and this process will be repeated three times every day (09.00, 12.00 and 15.00).
Study: NCT06705101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Group (Group G): Patients will receive 300 mg of oral Gabapentin
Description: In this study, the intervention involves administering 300 mg of oral gabapentin to patients in the intervention group two hours prior to surgery, aiming to assess its efficacy in attenuating the pressor response to laryngoscopy and tracheal intubation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The placebo group will receive an identical capsule without active medication, administered two hours before surgery, to compare its effects with those of gabapentin on the pressor response to laryngoscopy and tracheal intubation.
Study: NCT06704321

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-448
Description: 16 weeks of TOTUM-448 supplementation (4.284g/day corresponding to 8 capsules per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 16 weeks of placebo supplementation (8 capsules per day)
Study: NCT06706011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Patient
Description: Interactive Educational Activity
Study: NCT06706232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Two sequential administrations of 25 mg psilocybin, 4 weeks apart.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Support
Description: Five preparatory in-person psychotherapy sessions will be offered before the first administration session during weeks 1, 2, 3, 4, and 5. The optional second administration session will be preceded by a shorter 60 min preparatory session the day before.~Each administration session will be followed by 3 integration sessions and will adopt a Mindfulness-based CBT approach (M-CBT), in which a therapist will help the participant to process their experience and how to translate this into actual changes in everyday life.~If participants prefer more psychological support after the second administration session, they will be offered additional, optional therapy sessions for the duration of the trial regardless if they opted for a second administration session or not.
Study: NCT06704529

Intervention type: BEHAVIORAL
Intervention: pitching motion
Description: participants pitch fastball to the strike zone

Intervention type: BEHAVIORAL
Intervention: pitching motion
Description: participants pitch fastball to the strike zone
Study: NCT06706180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise for Mood video
Description: As per arm of the same name

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise for Fitness video
Description: As per arm of the same name
Study: NCT06704308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Application
Description: A web application for vaccine-hesitant parents and their teens with brief, 90-second narrative videos and tailored, motivational content

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Elaborated Prompts
Description: A component for providers that suggests elaborated prompts to be used with parents that align with the content of the web application, are tailored to parent concerns, and are motivational in nature
Study: NCT06706648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing-Led Psychological Capital Interventions
Description: The participating nurses received session about Nursing-Led Psychological Capital Interventions
Study: NCT06705920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical oxygen gel
Description: In the study group the gel will be applied over the suture and the patients will be instructed to apply the gel to the wound area and to the suture thread using a cotton swab
Study: NCT06704581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg BGM0504 injection
Description: 5mg BGM0504 injection administered subcutaneously (SC) once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg BGM0504 injection administered subcutaneously (SC) once a week
Description: 10mg BGM0504 injection administered subcutaneously (SC) once a week.
Study: NCT05264389

Intervention type: DEVICE
Intervention: Poly-Tape
Description: Poly-Tape Device for Medial Patellofemoral Ligament (MPFL) Reconstruction
Study: NCT06704581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg BGM0504 injection
Description: 15mg BGM0504 injection administered subcutaneously (SC) once a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BGM0504 placebo
Description: BGM0504 placebo administered SC once a week.
Study: NCT06705881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise program (EEP)
Description: All participants will perform a 6-week single-leg eccentric squat exercise. It will be performed on an incline board with a 25° incline. It will consist of a single-leg squat, with the downward component (eccentric phase) of the EEP performed using the symptomatic leg and the upward component (concentric phase) using the contralateral leg primarily. If pain occurs during the exercises, athletes will be asked to continue the exercise if they score ≤5 out of 10 on the Visual Acuity Scale (VAS). The exercises will be attempted in the first session of each week, and if no or very little pain is felt, the weight will be increased by 2.5% to increase the intensity of the exercise. Three sets of 15 repetitions per session will be performed twice a day. It will be performed 5 days a week. Participants will be asked to fill out an exercise diary (sets, repetitions, and daily frequency) and return it to the researchers at each follow-up session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercise program (EEP)
Description: All participants will perform a 6-week single-leg eccentric squat exercise. It will be performed on an incline board with a 25° incline. It will consist of a single-leg squat, with the downward component (eccentric phase) of the EEP performed using the symptomatic leg and the upward component (concentric phase) using the contralateral leg primarily. If pain occurs during the exercises, athletes will be asked to continue the exercise if they score ≤5 out of 10 on the Visual Acuity Scale (VAS). The exercises will be attempted in the first session of each week, and if no or very little pain is felt, the weight will be increased by 2.5% to increase the intensity of the exercise. Three sets of 15 repetitions per session will be performed twice a day. It will be performed 5 days a week. Participants will be asked to fill out an exercise diary (sets, repetitions, and daily frequency) and return it to the researchers at each follow-up session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT (Extracorporeal Shock Wave Therapy)
Description: ESWT is a therapy method routinely used in private and public hospitals. Tendinopathy therapy parameters approved by the International Society for Medical Shock Wave Therapy (ISMST) for focused ESWT treatment are: 0.10-0.25 mJ/mm (dosing appropriate to pain), up to a maximum of 5 Hz, 1500-2500 pulses per session, 1-2 weeks apart. Accordingly, in our study, the focused ESWT dosage of the ESWT group will be applied as; 0.10-0.25 mJ/mm (dosing appropriate to pain), 4 Hz, 2000 pulses, 1 session per week for 3 weeks. No exercise will be done on the day of ESWT.
Study: NCT06705985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of lateral meniscus prosthesis
Description: Implantation of a lateral meniscus prosthesis after meniscectomy.
Study: NCT04721223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3068
Description: JAB-3068 administrated orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3068
Description: JAB-3068 administrated orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1 inhibitor
Description: JS001 administrated as an intravenous(IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1 inhibitor
Description: JS001 administrated as an intravenous(IV) infusion.
Study: NCT05941702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Signal Integration Training
Description: Information and protocol uploaded to documents.
Study: NCT04580355

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-Stage Full Mouth Debridement
Description: Periodontal debridement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-Stage Full Mouth Debridement
Description: Periodontal debridement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500mg
Description: Administration of Amoxicillin 500mg prescribed on the day of treatment tid for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 400mg
Description: Administration of Metronidazole 400mg prescribed on the day of treatment tid for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Placebo
Description: Administration of Placebo on the day of treatment tid for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Placebo
Description: Administration of Placebo on the day of treatment tid for 7 days.
Study: NCT04906499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion
Description: After enrolling, participants will be outfitted with a Fitbit Charge 2 activity monitor. The monitor will be worn during all waking hours, and compliance will be considered as a day with ≥ 1,000 steps. Participants will complete a 14-day run-in observation period while wearing the Fitbit but no PA promotion will occur. Individuals who are noncompliant during the run in period (\<10 days with \<1,000 steps) will be removed. Participants will receive a text message each morning with a personalized, daily step count goal and a link used to confirm receipt of the goal. The preceding 10 days of step data will be rank ordered and the 60th percentile step count will be set as the goal for the next day.
Study: NCT04748861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indoor Cycling (IC)
Description: Participants will ride a Peloton bike 3x/week for 18 months.
Study: NCT05858541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Listening
Description: The LUCID AI-based system for song selection responds to the collected measurement data (video and HRV) and music preference information (like/dislike button, music taste profile) to recommend the playlist for the listener. The songs are selected using 76 different musical features and raw audio information. The system uses these features to recommend and optimize recommendations for the listener

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Listening to Audiobooks
Description: A selection of 40 audiobooks spanning 4 genres (10 each from Literary Classics, Fantasy, Mystery, Non-fiction) will be available. For each session, the participant and their caregiver will be given a prompt to make a genre selection. After making the genre selection, one of the ten stories associated with that genre will be selected at random. All stories were sampled from the Audible audiobook database. Stories had to be 30 minutes in length to align with the length of the music interventions and the selected stories had to have had a 4- or 5-star rating to ensure quality.
Study: NCT05134688

Intervention type: DRUG
Intervention: Magnesium sulfate
Description: Tocolytic to stop preterm labor
Study: NCT05493202

Intervention type: DEVICE
Intervention: Mira Fertility Tracker
Description: Non-interventional: observational, documenting urine E3G levels during gonadotropin stimulation.
Study: NCT06124781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A blood sample (48 ml) will be collected from each patient before performing the ROAT tests. This sample will be used to perform in vitro lymphocyte proliferation test, and cytokine measurements.
Study: NCT06220214

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CEDM
Description: Contrast Enhanced Digital Mammography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CEDBT
Description: Contrast-Enhanced Digital Breast Tomosynthesis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque 350mgI/mL Solution for Injection
Description: Injection of an FDA approved iodinated contrast agent is required to undergo the imaging procedures. It is not the intent of the study to evaluate the contrast agent, but it will be administered at the time of experimental imaging.
Study: NCT05314634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: concurrent exercise
Description: Participants conduct warm up for 5-min, aerobic exercise for 12-min, resistance exercise for 13-min, and 5-min cool down.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Participants conduct warm up for 5-min, resistance training for 25-min, and 5-min cool down.
Study: NCT06124781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsies
Description: 2 skin biopsies will be performed at the inclusion: one from positive/doubtful patch test reaction and one from control patch test. In case of positive ROAT test, 2 additional biopsies will be collected: one from positive ROAT test reaction and one from control area. Molecular analysis will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROAT test
Description: ROAT test (repeated open application test) is a use test used to establish the clinical relevance of patch tests. Patients will be exposed to 3 solutions of increasing concentration containing the culprit allergen (nickel, limonene hydroperoxide or linalool hydroperoxide), as well as a solution containing the vehicle alone (control solution), 2 times a day for up to 21 days, in the absence of a reaction.
Study: NCT05868902

Intervention type: DEVICE
Intervention: CardioFlux Magnetocardiography
Description: The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)

Intervention type: DEVICE
Intervention: CardioFlux Magnetocardiography
Description: The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
Study: NCT04696120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Patients who are randomly assigned to apixaban group will receive apixaban 5mg or 2.5mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients who are assigned to placebo group will receive placebo
Study: NCT05976087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensoExo
Description: combination of sensory feedback and the use of soft exoskeleton
Study: NCT06378229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (PEX010).
Study: NCT05642351

Intervention type: OTHER
Intervention: Autobiographical reminder
Description: The analysis of the specificity of Autobiographical Recall will be done through the following scale, developed for the study:~* 6 points for a recall involving a single personal event located in space AND time (e.g.,I remember when my parents took me to the sea for the first time..in 1962..in Dunkerque)~* 5 points for a recall involving a single personal event located in space OR time (I remember when my parents first took me to the sea...in 1962)~* 4 points for a recall involving a single personal event but without spatial/temporal details (I remember when my parents took me to the sea for the first time)~* 3 points for a recall involving a general personal event but located in space AND time (we used to go to Dunkerque in the summer)~* 2 points for a recall involving a general personal event but located in space OR time (we used to go to Dunkerque)~* 1 point for a recall involving a general personal event without spatial/temporal details (we used to go on vacation)

Intervention type: OTHER
Intervention: Autobiographical reminder
Description: The analysis of the specificity of Autobiographical Recall will be done through the following scale, developed for the study:~* 6 points for a recall involving a single personal event located in space AND time (e.g.,I remember when my parents took me to the sea for the first time..in 1962..in Dunkerque)~* 5 points for a recall involving a single personal event located in space OR time (I remember when my parents first took me to the sea...in 1962)~* 4 points for a recall involving a single personal event but without spatial/temporal details (I remember when my parents took me to the sea for the first time)~* 3 points for a recall involving a general personal event but located in space AND time (we used to go to Dunkerque in the summer)~* 2 points for a recall involving a general personal event but located in space OR time (we used to go to Dunkerque)~* 1 point for a recall involving a general personal event without spatial/temporal details (we used to go on vacation)
Study: NCT05959044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid Tablet
Description: oral 5mg tablet two times daily for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally 5mg two times daily for 8weeks
Study: NCT04715243

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula (HFNC)
Description: High flow nasal cannula as a form of non-invasive oxygen delivery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet NIV
Description: NIV interface
Study: NCT05243823

Intervention type: DRUG
Intervention: Vagifem®
Description: According to local clinical practice - independent of inclusion in this study

Intervention type: DRUG
Intervention: Vagifem®
Description: According to local clinical practice - independent of inclusion in this study

Intervention type: DRUG
Intervention: Non-Vagifem® LDVE, Estradiol
Description: According to local clinical practice - independent of inclusion in this study

Intervention type: DRUG
Intervention: Non-Vagifem® LDVE, Estradiol
Description: According to local clinical practice - independent of inclusion in this study
Study: NCT04615949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol, pharmaceutically produced with < 5 ppm THC
Description: CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
Study: NCT05528705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAENNEC
Description: Subacromial spatial administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% normal saline
Description: Subacromial spatial administration
Study: NCT06549478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo BgRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05635656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital symptom mapping and biofeedback treatment
Description: Digital symptom mapping and biofeedback treatment
Study: NCT03932903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPTS (ADherence Assessments and Personalized Timely Support).
Description: ADAPTS is a mobile app intervention that integrates contextually-tailored mobile messages and decision rules about when to deliver the messages, with the ultimate goal of improving oral chemotherapy adherence in AYAs with acute lymphoblastic leukemia and lymphoma. AYA participants will be micro-randomized to receive messages on some days that are adapted to their current characteristics (e.g., mood, pain, location) and designed to promote adherence, and no messages (no intervention) on other days. Other features in the app include a medication calendar that syncs with the electronic medication monitor (eCAP) to track daily adherence. A caregiver version of ADAPTS is also available, providing daily surveys (but no randomized mobile messages) and the medication calendar so that dyads can mutually track adherence.
Study: NCT05363553

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula based on whole goat milk
Description: Infant formula based on whole goat milk, nutritionally suitable for infants aged 0-6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: infant formula based on cow milk proteins
Description: Infant formula based on cow milk proteins, nutritionally suitable for infants aged 0-6 months
Study: NCT06031519

Intervention type: PROCEDURE
Intervention: Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)
Description: Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller; Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts up to 12 min, and the ablation power gradually increases from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).